FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Burrill & CO (Life Sciences GP), LLC 2. Date of Event Requiring Statement (Month/Day/Year) 04/26/2007 3. Issuer Name and Ticker or Trading Symbol Pharmasset Inc [VRUS] (Last) (First) (Middle) ONE EMBARCADERO CENTER, SUITE 2700 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SAN FRANCISCO, CA 94111 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 1,049,715 (1) I See footnotes (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Warrants	  (3)	08/04/2009	Common Stock	213,538 (4)	$ 0.1	I	See footnotes (2) (4)
Series D Preferred Stock	  (5)	  (5)	Common Stock	388,250 (6)	$ 0	I	See footnotes (2) (6)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Burrill & CO (Life Sciences GP), LLC ONE EMBARCADERO CENTER SUITE 2700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
Burrill & CO (Indiana GP), LLC ONE EMBARCADERO CENTER SUITE 2700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
BURRILL LIFE SCIENCES CAPITAL FUND LP ONE EMBARCADERO CENTER SUITE 2700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â
Burrill Indiana Life Sciences Capital Fund, L.P. ONE EMBARCADERO CENTER SUITE 2700 SAN FRANCISCO, CA 94111	Â	  X	Â	Â

Signatures

/s/ G. Steven Burrill, Managing Member, on behalf of Burrill & Company (Life Sciences GP), LLC		04/26/2007
**Signature of Reporting Person		Date
G. Steven Burrill, Managing Member		04/26/2007
**Signature of Reporting Person		Date
G. Steven Burrill, Managing Member of Burrill & Company (Life Sciences GP), LLC, its sole general partner		04/26/2007
**Signature of Reporting Person		Date
G. Steven Burrill, Managing Member of Burrill & Company (Indiana GP), LLC, its sole general partner		04/26/2007
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Consists of 858,857 shares held by Burrill Life Sciences Capital Fund, L.P. and 190,857 shares held by Burrill Indiana Life Sciences Capital Fund, L.P., after giving effect to a 1 for 1.5 reverse stock split that became effective on April 19, 2007.
(2)	The sole general partner of Burrill Life Sciences Capital Fund, L.P. is Burrill & Company (Life Sciences GP), LLC, and the sole general partner of Burrill Indiana Life Sciences Capital Fund, L.P. is Burrill & Company (Indiana GP), LLC. Burrill & Company (Life Sciences GP), LLC and Burrill & Company (Indiana GP), LLC are indirect beneficial owners of these securities and each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
(3)	The warrants expire upon completion of the public offering of the Issuer's Common Stock.
(4)	Consists of warrants to acquire 176,477 shares held by Burrill Life Sciences Capital Fund, L.P. and 39,217 shares held by Burrill Indiana Life Sciences Capital Fund, L.P., after giving effect to a 1 for 1.5 reverse stock split that became effective on April 19, 2007, and a reduction in the number of shares received pursuant to the election of a cashless exercise feature.
(5)	The shares of preferred stock reported herein are immediately convertible into Common Stock and have no expiration date.
(6)	Consists of 317,659 shares held by Burrill Life Sciences Capital Fund, L.P. and 70,591 shares held by Burrill Indiana Life Sciences Capital Fund, L.P., after giving effect to a 1 for 1.5 reverse stock split that became effective on April 19, 2007. Each share of Series D Preferred Stock is convertible into approximately 0.667 shares of Pharmasset common stock.
  Remarks: This Form 3 is being filed on behalf of 4 reporting persons as joint filers.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.